Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Cash from Investing Activities: 2020-2023

  • Journey Medical's Cash from Investing Activities rose 75.00% to -$5.0 million in Q1 2023 from the same period last year, while for Mar 2023 it was -$26.4 million, marking a year-over-year change of. This contributed to the annual value of -$15.0 million for FY2024, which is 200.00% down from last year.
  • Per Journey Medical's latest filing, its Cash from Investing Activities stood at -$5.0 million for Q1 2023, which was up 75.00% from -$20.0 million recorded in Q1 2022.
  • In the past 5 years, Journey Medical's Cash from Investing Activities ranged from a high of -$200,000 in Q4 2020 and a low of -$20.0 million during Q1 2022.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$5.0 million (2023), whereas its average is -$8.7 million.
  • Per our database at Business Quant, Journey Medical's Cash from Investing Activities plummeted by 500.00% in 2021 and then skyrocketed by 75.00% in 2023.
  • Quarterly analysis of 4 years shows Journey Medical's Cash from Investing Activities stood at -$200,000 in 2020, then crashed by 500.00% to -$1.2 million in 2021, then reached -$20.0 million in 2022, then surged by 75.00% to -$5.0 million in 2023.
  • Its last three reported values are -$5.0 million in Q1 2023, -$20.0 million for Q1 2022, and -$1.2 million during Q4 2021.